Optimizing the implementation of future treatment using surrogate end-points

Breast Cancer Res. 2008;10 Suppl 4(Suppl 4):S26. doi: 10.1186/bcr2186. Epub 2008 Dec 18.

Author

Mitch Dowsett¹

Affiliation

¹ Academic Department of Biochemistry, Royal Marsden Hospital, London, UK. mitch.dowsett@icr.ac.uk

PMID: 19128440
PMCID: PMC2614852
DOI: 10.1186/bcr2186

No abstract available

MeSH terms

Biomarkers / analysis*
Breast Neoplasms / metabolism
Breast Neoplasms / therapy*
Cell Proliferation
Clinical Trials as Topic
Female
Humans
Ki-67 Antigen / metabolism

Substances

Biomarkers
Ki-67 Antigen